The first reports the results of a preclinical study evaluating whether the early or late administration of an NGF-sequestering antibody (mAb 911) could attenuate tumor-induced nerve sprouting, neuroma formation, and subsequent cancer pain. This evidence concerns the gene NGF and cancer.